02.17.22
Opening the door to sale in the E.U., the European Food Safety Authority (EFSA) has granted Novel Food approval to Sabinsa for the company’s patented Curcumin C3 Reduct, which contains the curcuminoid metabolites tetrahydrocurcuminoids (THCs).
Sabinsa says its C3 Reduct overcomes bioavailability limitations of curcumin through its metabolites, particularly the reduced form of THCs, which confer essentially the same benefits of parent curcuminoids. Curcuminoids exert their effects through gastrointestinal as well as systemic routes, Sabinsa noted.
Research has demonstrated that C3 Reduct is a potent antioxidant, and that THCs exhibit anti-inflammatory activity. THCs have also been explored for colonic health.
“Gut resident bacteria also metabolize curcumin to THC, thus explaining many of the benefits that are ascribable to curcuminoids,” said Dr. Muhammed Majeed, founder and chairman of Sami-Sabinsa Group. “The benefits are comprehensively described in a recent monograph Sabinsa has published. Incidentally C3 Reduct is a fitting solution to the perceived limited systemic bioavailability of curcumin. I commend our technical and commercial teams that worked hard to reach this milestone.”
Sabinsa says its C3 Reduct overcomes bioavailability limitations of curcumin through its metabolites, particularly the reduced form of THCs, which confer essentially the same benefits of parent curcuminoids. Curcuminoids exert their effects through gastrointestinal as well as systemic routes, Sabinsa noted.
Research has demonstrated that C3 Reduct is a potent antioxidant, and that THCs exhibit anti-inflammatory activity. THCs have also been explored for colonic health.
“Gut resident bacteria also metabolize curcumin to THC, thus explaining many of the benefits that are ascribable to curcuminoids,” said Dr. Muhammed Majeed, founder and chairman of Sami-Sabinsa Group. “The benefits are comprehensively described in a recent monograph Sabinsa has published. Incidentally C3 Reduct is a fitting solution to the perceived limited systemic bioavailability of curcumin. I commend our technical and commercial teams that worked hard to reach this milestone.”
